Multi-dimensional roles of sodium-glucose cotransporter 2 inhibitors: beyond hypoglycemic and cardiorenal protection
Abstract
Sodium glucose cotransporter-2 inhibitors (SGLT2i) have been found to have a range of benefits, including improving obesity and insulin resistance, hyperuricemia, hypertension, hyperlipidemia, and other metabolic disorders. Initially used for the hypoglycemic effects, they are now found to benefit atherosclerotic cardiovascular disease and chronic kidney disease. Additionally, SGLT2i has been found to have multiple functions, such as improving liver metabolism, affecting brain function, protecting islet β cell function, anti-tumor, and affecting immune system function. This review provides an overview of the protective effects of SGLT2i on different organs and tissues, as well as the potential mechanisms underlying the functional improvement induced by SGLT2i in recent years.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.